TCG Labs Soleil Begins Three Phase 1 Clinical Trials
The San Francisco lab accelerates its portfolio development with the launch of its first human clinical studies.
Updated on Oct. 28, 2026 in Biotech
Live Poll
Do you trust that venture-biotech company models successfully deliver new medical treatments to patients?
TCG Labs Soleil has initiated Phase 1 clinical trials for three therapeutic programs developed within its San Francisco-based R&D hub. These trials mark the first-in-human studies for these specific candidates, with a fourth program for respiratory disease approaching clinical development.
Why it matters
The company operates an in-house model to rapidly advance therapeutic programs through independent portfolio companies, aiming to create high-confidence opportunities for biopharma partners. This structure allows the lab to move science toward clinical patients while managing multiple distinct therapeutic assets simultaneously.
The clinical trials for DBC-664, JUR-003, and ARG-397 are currently evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in human subjects. These programs represent three of 19 total portfolio companies built by the lab since its 2024 inception.
The players
TCG Labs Soleil
A San Francisco-based R&D hub that builds and scales independent portfolio companies to develop new therapeutic programs.
Duboce Biopharmaceuticals
A TCG Labs Soleil portfolio company currently evaluating the drug DBC-664 for solid tumors.
Juri Biosciences
A TCG Labs Soleil portfolio company evaluating the drug JUR-003 for metastatic prostate cancer.
Arguello Biosciences
A TCG Labs Soleil portfolio company evaluating the drug ARG-397 for thromboembolic disorders.
Clement Therapeutics
A TCG Labs Soleil portfolio company developing the antibody CMT-133 for inflammatory respiratory diseases.
The details
TCG Labs Soleil uses an internal R&D hub to incubate and spin out independent entities that manage specific drug development pipelines. The current trials test candidates for solid tumors, metastatic prostate cancer, and thromboembolic disorders through focused clinical protocols. Clement Therapeutics, another portfolio company, has completed IND-enabling studies—tests required by regulators before an Investigational New Drug application is approved—for its CMT-133 antibody targeting inflammatory respiratory diseases.
Timeline
2024: TCG Labs Soleil launched its in-house R&D hub.
October 28, 2026: TCG Labs Soleil announced the clinical trial initiation.
Remaining 2026: Planned first-in-human clinical trial for CMT-133.
2026: European Respiratory Society Congress.
The Tech Race
TCG Labs Soleil is scaling its internal R&D model to simultaneously shepherd multiple independent companies through the high-risk Phase 1 clinical environment. This expansion tracks the company's rapid growth from a 2024 launch to maintaining a 19-company portfolio.
These clinical trials represent early-stage research and are not currently available as medical treatments for patients. Readers following oncology or hematology developments can look for results from these Phase 1a/1b studies as the trials progress through their initial safety and efficacy milestones.
The takeaway
TCG Labs Soleil is moving its internal R&D projects into human trials, marking a shift from corporate formation to clinical data gathering. Watch for clinical efficacy results from the current Phase 1 trials and the scheduled start of the Clement Therapeutics study later this year.
What happens next
Clement Therapeutics plans to initiate a first-in-human clinical trial for its CMT-133 antibody before the end of 2026.
Further reading
For more updates on regional developments, visit the Biotech section.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust that venture-biotech company models successfully deliver new medical treatments to patients?
